Ascendis Pharma (ASND) Stock Forecast & Price Target

Compare

680 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ASND Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Ascendis

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$267.64

▲(30.03% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $267.64 with a high forecast of $325.00 and a low forecast of $240.00. The average price target represents a 30.03% change from the last price of $205.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"129":"$129","326":"$326","178.25":"$178.3","227.5":"$227.5","276.75":"$276.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$325.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":267.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$267.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":240,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$240.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[129,178.25,227.5,276.75,326],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.24,221.83692307692309,230.43384615384616,239.03076923076924,247.6276923076923,256.2246153846154,264.82153846153847,273.41846153846154,282.0153846153846,290.6123076923077,299.20923076923077,307.80615384615385,316.4030769230769,{"y":325,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.24,217.42461538461538,221.60923076923078,225.79384615384615,229.97846153846154,234.16307692307691,238.3476923076923,242.53230769230768,246.71692307692308,250.90153846153845,255.08615384615385,259.27076923076925,263.4553846153846,{"y":267.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,213.24,215.29846153846154,217.3569230769231,219.41538461538462,221.47384615384615,223.5323076923077,225.59076923076924,227.64923076923077,229.7076923076923,231.76615384615386,233.82461538461538,235.88307692307694,237.94153846153847,{"y":240,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.24,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$325.00

Average Price Target$267.64

Lowest Price Target$240.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yun Zhong

Wedbush

$240

Buy

16.60%

Upside

Reiterated

01/16/26

Ascendis Pharma: Sustained Commercial Momentum and TransCon Pipeline Catalysts Underpin Buy Rating

Maxwell Skor

Morgan Stanley

$250

Buy

21.46%

Upside

Reiterated

01/14/26

Ascendis Pharma: Vision 2030 Growth Story Driven by Yorvipath and Late‑Stage TransCon Pipeline Justifies Buy Rating

Tazeen Ahmad

Bank of America Securities

$242→$246

Buy

19.52%

Upside

Reiterated

01/12/26

We reiterate our Buy with new $246 PO.

Li Watsek

Cantor Fitzgerald

$254

Buy

23.40%

Upside

Reiterated

01/11/26

Alex Thompson CFA

Stifel Nicolaus

$256

Buy

24.37%

Upside

Reiterated

01/09/26

Stifel Nicolaus Sticks to Its Buy Rating for Ascendis Pharma (ASND)

Derek Archila

Wells Fargo

$297→$322

Buy

56.44%

Upside

Reiterated

01/09/26

Wells Fargo Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Gavin Clark-Gartner

Evercore ISI

$305

Buy

48.18%

Upside

Reiterated

01/09/26

Luca Issi

RBC Capital

$240→$245

Buy

19.03%

Upside

Reiterated

01/08/26

Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Elicio Therapeutics (ELTX)

Steven Alexopoulos

TD Cowen

$325

Buy

57.90%

Upside

Reiterated

01/07/26

TD Cowen Analyst Highlights Ascendis Pharma as Priority Healthcare Name With Buy Rating and Expected Outperformance

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

$255

Buy

23.89%

Upside

Initiated

11/17/25

Ascendis Pharma initiated with an Outperform at Wolfe ResearchAscendis Pharma initiated with an Outperform at Wolfe Research

Jessica Fye

J.P. Morgan

Buy

―

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Alkermes (NASDAQ: ALKS)

Leland Gershell

Oppenheimer

$246

Buy

19.52%

Upside

Reiterated

11/13/25

Oppenheimer Remains a Buy on Ascendis Pharma (ASND)

Martin Auster

Raymond James

$271

Buy

31.66%

Upside

Initiated

10/17/25

Ascendis Pharma initiated with a Strong Buy at Raymond JamesAscendis Pharma initiated with a Strong Buy at Raymond James

Joseph Schwartz

Leerink Partners

$225

Buy

9.31%

Upside

Reiterated

09/23/25

Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Eliana Merle

UBS

$307

Buy

49.15%

Upside

Reiterated

09/22/25

Ascendis Pharma's Market Leadership and Growth Potential in Chronic Hypoparathyroidism

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yun Zhong

Wedbush

$240

Buy

16.60%

Upside

Reiterated

01/16/26

Ascendis Pharma: Sustained Commercial Momentum and TransCon Pipeline Catalysts Underpin Buy Rating

Maxwell Skor

Morgan Stanley

$250

Buy

21.46%

Upside

Reiterated

01/14/26

Ascendis Pharma: Vision 2030 Growth Story Driven by Yorvipath and Late‑Stage TransCon Pipeline Justifies Buy Rating

Tazeen Ahmad

Bank of America Securities

$242→$246

Buy

19.52%

Upside

Reiterated

01/12/26

We reiterate our Buy with new $246 PO.

Li Watsek

Cantor Fitzgerald

$254

Buy

23.40%

Upside

Reiterated

01/11/26

Alex Thompson CFA

Stifel Nicolaus

$256

Buy

24.37%

Upside

Reiterated

01/09/26

Stifel Nicolaus Sticks to Its Buy Rating for Ascendis Pharma (ASND)

Derek Archila

Wells Fargo

$297→$322

Buy

56.44%

Upside

Reiterated

01/09/26

Wells Fargo Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Gavin Clark-Gartner

Evercore ISI

$305

Buy

48.18%

Upside

Reiterated

01/09/26

Luca Issi

RBC Capital

$240→$245

Buy

19.03%

Upside

Reiterated

01/08/26

Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Elicio Therapeutics (ELTX)

Steven Alexopoulos

TD Cowen

$325

Buy

57.90%

Upside

Reiterated

01/07/26

TD Cowen Analyst Highlights Ascendis Pharma as Priority Healthcare Name With Buy Rating and Expected Outperformance

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

$255

Buy

23.89%

Upside

Initiated

11/17/25

Ascendis Pharma initiated with an Outperform at Wolfe ResearchAscendis Pharma initiated with an Outperform at Wolfe Research

Jessica Fye

J.P. Morgan

Buy

―

Reiterated

11/13/25

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Alkermes (NASDAQ: ALKS)

Leland Gershell

Oppenheimer

$246

Buy

19.52%

Upside

Reiterated

11/13/25

Oppenheimer Remains a Buy on Ascendis Pharma (ASND)

Martin Auster

Raymond James

$271

Buy

31.66%

Upside

Initiated

10/17/25

Ascendis Pharma initiated with a Strong Buy at Raymond JamesAscendis Pharma initiated with a Strong Buy at Raymond James

Joseph Schwartz

Leerink Partners

$225

Buy

9.31%

Upside

Reiterated

09/23/25

Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

Eliana Merle

UBS

$307

Buy

49.15%

Upside

Reiterated

09/22/25

Ascendis Pharma's Market Leadership and Growth Potential in Chronic Hypoparathyroidism

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

3 Months

xxx

Success Rate

20/26 ratings generated profit

Average Return

+10.76%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +10.76% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

29/33 ratings generated profit

Average Return

+27.74%

reiterated a buy rating 7 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 87.88% of your transactions generating a profit, with an average return of +27.74% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+62.08%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +62.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ASND has received 33 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 267.64.

Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Next quarter’s earnings estimate for ASND is -$0.14 with a range of -$2.59 to $0.43. The previous quarter’s EPS was -$1.16. ASND beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.

ASND Sales Forecast

Next quarter’s sales forecast for ASND is $285.71M with a range of $262.56M to $300.17M. The previous quarter’s sales results were $249.64M. ASND beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ASND has Performed in-line its overall industry.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?

Based on analyst ratings, Ascendis Pharma’s 12-month average price target is 267.64.

What is ASND’s upside potential, based on the analysts’ average price target?

Ascendis Pharma has 30.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ASND a Buy, Sell or Hold?

Ascendis Pharma has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ascendis Pharma’s price target?

The average price target for Ascendis Pharma is 267.64. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $325.00 ,the lowest forecast is $240.00. The average price target represents 30.03% Increase from the current price of $205.83.

What do analysts say about Ascendis Pharma?

Ascendis Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of ASND?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ascendis Pharma (ASND) Stock Forecast & Price Target

ASND Analyst Ratings

ASND Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ascendis Pharma

ASND Analyst Recommendation Trends

ASND Financial Forecast

ASND Earnings Forecast

ASND Sales Forecast

ASND Stock Forecast FAQ

Detailed List of Analyst Forecasts